SB11 (Proposed Ranibizumab biosimilar)

ranibizumab · Samsung Bioepis Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SB11 (Proposed Ranibizumab biosimilar), covering 2021-05-21 to 2021-05-21. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]

See pricing